$OPK
OPKO HEALTH, INC. Stock $opk

$opk Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000094480922000026 Filed on May 09, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021 Q1
Revenue	$329.2M	$401.3M	$545.2M
YoY Change	-39.61%	-18.87%	157.8%
Cost Of Revenue	$243.9M	$292.8M	$363.5M
YoY Change	-32.91%	-8.12%	159.09%
Gross Profit	$85.34M	$108.5M	$181.7M
YoY Change	-53.03%	-38.31%	155.2%
Gross Profit Margin	25.92%	27.04%	33.33%
Selling, General & Admin	$117.5M	$138.2M	$112.3M
YoY Change	4.68%	35.77%	47.49%
% of Gross Profit	137.72%	127.38%	61.8%
Research & Development	$18.31M	$21.01M	$19.32M
YoY Change	-5.19%	20.04%	-11.24%
% of Gross Profit	21.46%	19.36%	10.63%
Depreciation & Amortization	$27.81M	$19.19M	$19.99M
YoY Change	39.15%	-4.52%	-9.36%
% of Gross Profit	32.59%	17.69%	11.0%
Operating Expenses	$401.6M	$464.4M	$506.7M
YoY Change	-20.74%	4.29%	100.9%
Operating Profit	-$72.42M	-$355.9M	$38.44M
YoY Change	-288.42%	32.1%	-194.3%
Interest Expense	-$2.784M	-$4.026M	-$5.800M
YoY Change	-52.0%	-26.8%	23.4%
% of Operating Profit			-15.09%
Other Income/Expense, Net	-$4.226M	$1.297M	-$6.756M
YoY Change	-37.45%	-38.24%	-60.41%
Pretax Income	-$76.65M	-$65.81M	$31.68M
YoY Change	-341.94%	-243.38%	-154.79%
Income Tax	-$21.27M	$7.496M	$560.0K
% Of Pretax Income			1.77%
Net Earnings	-$55.43M	-$73.77M	$31.08M
YoY Change	-278.37%	-328.42%	-152.56%
Net Earnings / Revenue	-16.84%	-18.38%	5.7%
Basic Earnings Per Share	-$0.08	-$0.11	$0.05
Diluted Earnings Per Share	-$0.08	-$0.11	$0.05
COMMON SHARES
Basic Shares Outstanding	660.3M shares	681.3M shares	640.9M shares
Diluted Shares Outstanding	660.3M shares		640.9M shares

Balance Sheet

Concept	2022 Q1	2021 Q4	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$102.3M	$134.7M	$89.50M
YoY Change	14.28%	86.58%	159.42%
Cash & Equivalents	$102.3M	$134.7M	$89.50M
Short-Term Investments
Other Short-Term Assets	$4.832M	$6.195M	$5.063M
YoY Change	-4.56%	16.69%	-67.93%
Inventory	$99.41M	$86.50M	$159.1M
Prepaid Expenses
Receivables	$212.8M	$259.6M	$320.5M
Other Receivables	$8.540M	$5.951M	$9.800M
Total Short-Term Assets	$754.1M	$823.0M	$599.0M
YoY Change	25.88%	57.31%	118.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$124.7M	$124.0M	$139.1M
YoY Change	-10.36%	-11.81%	9.24%
Goodwill	$710.4M	$520.6M	$718.6M
YoY Change	-1.14%	-23.51%	1.22%
Intangibles
YoY Change
Long-Term Investments	$9.472M	$10.73M	$10.40M
YoY Change	-8.92%	-31.66%	-1.89%
Other Assets	$9.100M	$9.534M	$9.745M
YoY Change	-6.62%	-5.23%	38.7%
Total Long-Term Assets	$1.553B	$1.577B	$1.921B
YoY Change	-19.15%	-19.14%	-1.92%
TOTAL ASSETS
Total Short-Term Assets	$754.1M	$823.0M	$599.0M
Total Long-Term Assets	$1.553B	$1.577B	$1.921B
Total Assets	$2.307B	$2.400B	$2.520B
YoY Change	-8.44%	-2.97%	12.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$94.24M	$82.04M	$162.7M
YoY Change	-42.07%	-18.68%	191.21%
Accrued Expenses	$157.3M	$193.5M	$213.1M
YoY Change	-26.18%	-19.67%	29.21%
Deferred Revenue	$258.0K	$258.0K	$15.03M
YoY Change	-98.28%	-98.37%	43.77%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$19.86M	$16.95M	$20.10M
YoY Change	-1.18%	-37.68%	30.52%
Total Short-Term Liabilities	$309.2M	$330.0M	$403.9M
YoY Change	-23.46%	-12.11%	64.81%
LONG-TERM LIABILITIES
Long-Term Debt	$216.4M	$193.1M	$3.325M
YoY Change	6407.01%	4932.13%	-6.02%
Other Long-Term Liabilities	$15.66M	$15.06M	$26.71M
YoY Change	-41.38%	-59.37%	-65.65%
Total Long-Term Liabilities	$382.8M	$384.6M	$419.1M
YoY Change	-8.67%	-9.73%	-4.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$309.2M	$330.0M	$403.9M
Total Long-Term Liabilities	$382.8M	$384.6M	$419.1M
Total Liabilities	$692.0M	$714.6M	$823.1M
YoY Change	-15.93%	-10.84%	20.34%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.550B	-$1.512B	-$1.451B
YoY Change	6.84%	2.03%	-7.69%
Common Stock	$6.902M	$6.901M	$6.707M
YoY Change	2.91%	2.91%	0.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.791M	$1.791M	$1.791M
YoY Change	0.0%	0.0%	0.0%
Treasury Stock Shares	8.655M shares	8.655M shares	549.9K shares
Shareholders Equity	$1.615B	$1.685B	$1.697B
YoY Change
Total Liabilities & Shareholders Equity	$2.307B	$2.400B	$2.520B
YoY Change	-8.44%	-2.97%	12.86%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021 Q1
OPERATING ACTIVITIES
Net Income	-$55.43M	-$73.77M	$31.08M
YoY Change	-278.37%	-328.42%	-152.56%
Depreciation, Depletion And Amortization	$27.81M	$19.19M	$19.99M
YoY Change	39.15%	-4.52%	-9.36%
Cash From Operating Activities	-$19.86M	-$5.643M	$26.04M
YoY Change	-176.26%	-116.45%	-160.03%
INVESTING ACTIVITIES
Capital Expenditures	-$5.251M	-$6.730M	-$9.200M
YoY Change	-42.92%	-1.03%	64.29%
Acquisitions
YoY Change
Other Investing Activities	$348.0K	-$1.949M	$8.100M
YoY Change	-95.7%	-2049.0%
Cash From Investing Activities	-$4.903M	-$8.679M	-$1.106M
YoY Change	343.31%	29.54%	-80.32%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$7.891M	832.0K	-$7.192M
YoY Change	9.72%	-89.73%	346.43%
NET CHANGE
Cash From Operating Activities	-$19.86M	-5.643M	$26.04M
Cash From Investing Activities	-$4.903M	-8.679M	-$1.106M
Cash From Financing Activities	-$7.891M	832.0K	-$7.192M
Net Change In Cash	-$32.43M	-13.49M	$17.29M
YoY Change	-287.54%	-137.79%	-133.96%
FREE CASH FLOW
Cash From Operating Activities	-$19.86M	-$5.643M	$26.04M
Capital Expenditures	-$5.251M	-$6.730M	-$9.200M
Free Cash Flow	-$14.61M	$1.087M	$35.24M
YoY Change	-141.45%	-97.36%	-193.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000944809
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2021-01-31#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-33528
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	OPKO Health, Inc.
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-2402409
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	4400 Biscayne Blvd.
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Miami
CY2022Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33137
CY2022Q1	dei	City Area Code CityAreaCode	(305)
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	575-4100
CY2022Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
CY2022Q1	dei	Trading Symbol TradingSymbol	OPK
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	681525181	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	102281000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	134710000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	212755000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	259637000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	99406000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	86502000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23274000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27170000	USD
CY2022Q1	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	316353000	USD
CY2021Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group AssetsHeldForSaleNotPartOfDisposalGroup	314994000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	754069000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	823013000	USD
CY2022Q1	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	81899000	USD
CY2021Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	79727000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	890498000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	321683000	USD
CY2022Q1	opk	In Process Researchand Development InProcessResearchandDevelopment	0	USD
CY2021Q4	opk	In Process Researchand Development InProcessResearchandDevelopment	590200000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	519052000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	520601000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	9472000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	10729000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42768000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44228000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9100000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9534000	USD
CY2022Q1	us-gaap	Assets Assets	2306858000	USD
CY2021Q4	us-gaap	Assets Assets	2399715000	USD
CY2022Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	94240000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	82040000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	157316000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193493000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11690000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11624000	USD
CY2022Q1	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	28512000	USD
CY2021Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	28156000	USD
CY2022Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	17412000	USD
CY2021Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	14695000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	309170000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	330008000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31596000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33097000	USD
CY2022Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	210520000	USD
CY2021Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	187935000	USD
CY2022Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	125030000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	148487000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15658000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15062000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	382804000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	384581000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	691974000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	714589000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000	shares
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	690138033	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	690082283	shares
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	6902000	USD
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	6901000	USD
CY2022Q1	us-gaap	Treasury Stock Shares TreasuryStockShares	8655082	shares
CY2021Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	8655082	shares
CY2022Q1	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1791000	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3191139000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	3222487000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-31415000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-30495000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1549951000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1511976000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614884000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1685126000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2306858000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2399715000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	329219000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	545165000	USD
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	117537000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	112286000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18312000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19315000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-106000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-957000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22025000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12577000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	401643000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	506728000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72424000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	38437000	USD
CY2022Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	10000	USD
CY2021Q1	opk	Interest Income Nonoperating InterestIncomeNonoperating	5000	USD
CY2022Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	2662000	USD
CY2021Q1	opk	Interest Expense Nonoperating InterestExpenseNonoperating	5395000	USD
CY2022Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-132000	USD
CY2021Q1	us-gaap	Gain Loss On Derivative Instruments Net Pretax GainLossOnDerivativeInstrumentsNetPretax	-439000	USD
CY2022Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1442000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-927000	USD
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4226000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6756000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-76650000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	31681000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-21266000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	560000	USD
CY2022Q1	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	-55384000	USD
CY2021Q1	opk	Income Loss From Continuing Operations Before Investments In Investees Extraordinary Items Net Of Tax IncomeLossFromContinuingOperationsBeforeInvestmentsInInvesteesExtraordinaryItemsNetOfTax	31121000	USD
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-49000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.05
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.05
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	660302426	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	660302426	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	640853200	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	640853200	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-920000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-9070000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56353000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	22008000	USD
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1685126000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7617000	USD
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	136000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-920000	USD
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1614884000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1671551000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2647000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	308000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-9070000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1696514000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-55433000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	31078000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27814000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19989000	USD
CY2022Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	678000	USD
CY2021Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	2585000	USD
CY2022Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	281000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	222000	USD
CY2022Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-49000	USD
CY2021Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-43000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	7617000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2647000	USD
CY2022Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-61000	USD
CY2021Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3039000	USD
CY2022Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	-1299000	USD
CY2021Q1	opk	Increase Decrease In Equity Securities Fvni And Derivative Instruments IncreaseDecreaseInEquitySecuritiesFVNIAndDerivativeInstruments	279000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-106000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-957000	USD
CY2022Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22356000	USD
CY2021Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1033000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-44421000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	35238000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	9463000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	27912000	USD
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2612000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1415000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-511000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1255000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	16143000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	62231000	USD
CY2022Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	2197000	USD
CY2021Q1	opk	Increase Decreasein Foreign Currency Measurement IncreaseDecreaseinForeignCurrencyMeasurement	946000	USD
CY2022Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-4000	USD
CY2021Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-790000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-36177000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-27126000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19856000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	26037000	USD
CY2022Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
CY2021Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	8079000	USD
CY2022Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	348000	USD
CY2021Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	60000	USD
CY2022Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	5251000	USD
CY2021Q1	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	9245000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4903000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1106000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	136000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	308000	USD
CY2022Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1649166000	USD
CY2021Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	472213000	USD
CY2022Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	1657193000	USD
CY2021Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	479713000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7891000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7192000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	221000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-447000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-32429000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	17292000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	134710000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	72211000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102281000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89503000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	3420000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	4689000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1063000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1470000	USD
CY2022Q1	opk	Numberof Sales Employees NumberofSalesEmployees	250	employee
CY2021Q3	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	31500000	USD
CY2022Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and </span>liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ significantly from these estimates.
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	600000	USD
CY2021Q1	us-gaap	Inventory Write Down InventoryWriteDown	3100000	USD
CY2021Q4	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1400000000	USD
CY2022Q1	opk	Business Combination Recognized Identifiable Assets Acquiredand Liabilities Assumed Goodwilland Intangible Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredandLiabilitiesAssumedGoodwillandIntangibleAssets	1400000000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	519100000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	520600000	USD
CY2022Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	890500000	USD
CY2021Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	911900000	USD
CY2022Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	22000000	USD
CY2021Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	12600000	USD
CY2022Q1	us-gaap	Depreciation Depreciation	5800000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	7400000	USD
CY2022Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of credit risk and allowance for credit losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Financial instruments that potentially subject us to concentrations of credit risk consist primarily of accounts receivable. Substantially all of our accounts receivable are with either companies in the healthcare industry or patients. However, credit risk is limited due to the number of our clients as well as their dispersion across many different geographic regions.</span>While we have receivables due from federal and state governmental agencies, we do not believe that such receivables represent a credit risk because the related healthcare programs are funded by federal and state governments, and payment is primarily dependent upon submitting appropriate documentation.
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2000000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1800000	USD
CY2022Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	100000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	300000	USD
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7600000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2600000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1100000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	4800000	USD
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	55750	shares
CY2022Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	55750	shares
CY2022Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	55750	shares
CY2022Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2021Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	117500	shares
CY2021Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised Netof Shares Surrenderedin Lieuof Cash Payment StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercisedNetofSharesSurrenderedinLieuofCashPayment	117500	shares
CY2021Q1	opk	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	117500	shares
CY2021Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2021Q1	opk	Shares Surrendered In Lieu Of Cash Payment SharesSurrenderedInLieuOfCashPayment	0	shares
CY2022Q1	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	214734000	USD
CY2021Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	261476000	USD
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1979000	USD
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1839000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	212755000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	259637000	USD
CY2022Q1	us-gaap	Other Inventory Supplies OtherInventorySupplies	48740000	USD
CY2021Q4	us-gaap	Other Inventory Supplies OtherInventorySupplies	39447000	USD
CY2022Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	46594000	USD
CY2021Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	44107000	USD
CY2022Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	2795000	USD
CY2021Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1615000	USD
CY2022Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	6435000	USD
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6112000	USD
CY2022Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	5158000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	4779000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	99406000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	86502000	USD
CY2022Q1	opk	Taxes Recoverable Current TaxesRecoverableCurrent	6105000	USD
CY2021Q4	opk	Taxes Recoverable Current TaxesRecoverableCurrent	5598000	USD
CY2022Q1	us-gaap	Supplies Supplies	8171000	USD
CY2021Q4	us-gaap	Supplies Supplies	10641000	USD
CY2022Q1	us-gaap	Prepaid Insurance PrepaidInsurance	1731000	USD
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	4383000	USD
CY2022Q1	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	2435000	USD
CY2021Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	353000	USD
CY2022Q1	us-gaap	Other Assets Current OtherAssetsCurrent	4832000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	6195000	USD
CY2022Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	23274000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	27170000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	338294000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	320820000	USD
CY2022Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	890498000	USD
CY2021Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	321683000	USD
CY2022Q1	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	22811000	USD
CY2021Q4	opk	Inventory Received Not Invoiced Current InventoryReceivedNotInvoicedCurrent	40446000	USD
CY2022Q1	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	26940000	USD
CY2021Q4	opk	Accrued Commitmentsand Contingencies Current AccruedCommitmentsandContingenciesCurrent	27819000	USD
CY2022Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	50332000	USD
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	45939000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	258000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	258000	USD
CY2022Q1	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4167000	USD
CY2021Q4	opk	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	4867000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Current BusinessCombinationContingentConsiderationLiabilityCurrent	487000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2451000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2257000	USD
CY2022Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2717000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2121000	USD
CY2022Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	47153000	USD
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	69299000	USD
CY2022Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	157316000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	193493000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2242000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2350000	USD
CY2022Q1	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1973000	USD
CY2021Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	2224000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3865000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2924000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	204000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	208000	USD
CY2022Q1	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	7374000	USD
CY2021Q4	us-gaap	Other Liabilities And Deferred Revenue Noncurrent OtherLiabilitiesAndDeferredRevenueNoncurrent	7356000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15658000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	15062000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	710408000	USD
CY2021Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	38023000	USD
CY2022Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-153333000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	519052000	USD
CY2022Q1	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	217000	USD
CY2022Q1	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	4497000	USD
CY2021Q4	opk	Equity Method Investment Excluding Variable Interest Entity EquityMethodInvestmentExcludingVariableInterestEntity	263000	USD
CY2021Q4	us-gaap	Equity Method Investment Underlying Equity In Net Assets EquityMethodInvestmentUnderlyingEquityInNetAssets	3577000	USD
CY2022Q1	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	773000	USD
CY2022Q1	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	2772000	USD
CY2021Q4	opk	Equity Method Investment Variable Interest Entity EquityMethodInvestmentVariableInterestEntity	816000	USD
CY2021Q4	opk	Equity Method Investment Variable Interest Entity Underlying Equity In Net Assets EquityMethodInvestmentVariableInterestEntityUnderlyingEquityInNetAssets	3043000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3064000	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4226000	USD
CY2022Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5403000	USD
CY2021Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	5408000	USD
CY2022Q1	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	15000	USD
CY2021Q4	opk	Stock Optionand Warrant Investments StockOptionandWarrantInvestments	16000	USD
CY2022Q1	us-gaap	Long Term Investments LongTermInvestments	9472000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	10729000	USD
CY2022Q1	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	3600000	USD
CY2021Q4	us-gaap	Equity Method Investment Quoted Market Value EquityMethodInvestmentQuotedMarketValue	4500000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-1162000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	2780000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2981000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1162000	USD
CY2021Q1	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-201000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	230264000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	205272000	USD
CY2022Q1	us-gaap	Long Term Debt LongTermDebt	230264000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	205272000	USD
CY2021Q4	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	13	institution
CY2022Q1	opk	Debt Instruments Numberof Financial Institutions DebtInstrumentsNumberofFinancialInstitutions	13	institution
CY2022Q1	us-gaap	Line Of Credit Facility Maximum Borrowing Capacity LineOfCreditFacilityMaximumBorrowingCapacity	103204000	USD
CY2022Q1	us-gaap	Line Of Credit LineOfCredit	16531000	USD
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	13672000	USD
CY2022Q1	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	3064000	USD
CY2022Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	3079000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2729000	USD
CY2022Q1	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3191000	USD
CY2021Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	4226000	USD
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	4364000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2837000	USD
CY2021Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	2837000	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2700000	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2800000	USD
CY2022Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	31000	USD
CY2021Q1	us-gaap	Related Party Transaction Expenses From Transactions With Related Party RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty	0	USD
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	2700000	USD
CY2022Q1	us-gaap	Purchase Obligation PurchaseObligation	252400000	USD
CY2022Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	2000000	USD
CY2021Q1	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	28000000	USD
CY2022Q1	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	2100000	USD
CY2021Q4	opk	Accrued Expense Payor Overpayment Reimbursement Liability AccruedExpensePayorOverpaymentReimbursementLiability	5000000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	466000	USD
CY2022Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	462000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	4000	USD
CY2022Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-72424000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	38437000	USD
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27814000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19989000	USD
CY2022Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-49000	USD
CY2021Q1	us-gaap	Gain Loss On Investments GainLossOnInvestments	-43000	USD
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	329219000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	545165000	USD
CY2022Q1	us-gaap	Assets Assets	2306858000	USD
CY2021Q4	us-gaap	Assets Assets	2399715000	USD
CY2022Q1	us-gaap	Goodwill Goodwill	519052000	USD
CY2021Q4	us-gaap	Goodwill Goodwill	520601000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	42768000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44228000	USD
CY2022Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	6316000	USD
CY2021Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	5181000	USD
CY2022Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11690000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	11624000	USD
CY2022Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2451000	USD
CY2021Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	2257000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	31596000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	33097000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	6682000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	10429000	USD
CY2022Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	3865000	USD
CY2021Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	2924000	USD
CY2022Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y1M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2022Q1	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y4M24D
CY2022Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.045
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.046
CY2022Q1	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.058
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.048
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	10435000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Remainder Of Fiscal Year FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear	1930000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	10115000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	2050000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	8220000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	1454000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5847000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	919000	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	5397000	USD
CY2022Q1	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	329000	USD
CY2022Q1	opk	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	24621000	USD
CY2022Q1	opk	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	0	USD
CY2022Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	64635000	USD
CY2022Q1	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	366000	USD
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	54206000	USD
CY2022Q1	us-gaap	Finance Lease Liability FinanceLeaseLiability	6316000	USD
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4600000	USD
CY2022Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	700000	USD
CY2022Q1	us-gaap	Variable Lease Cost VariableLeaseCost	400000	USD
CY2021Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	4500000	USD
CY2021Q1	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	600000	USD
CY2021Q1	us-gaap	Variable Lease Cost VariableLeaseCost	700000	USD
CY2022Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4288000	USD
CY2021Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4245000	USD
CY2022Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	33000	USD
CY2021Q1	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	33000	USD
CY2022Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	498000	USD
CY2021Q1	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	525000	USD
CY2022Q1	opk	Payments For Leases PaymentsForLeases	4819000	USD
CY2021Q1	opk	Payments For Leases PaymentsForLeases	4803000	USD

Files In Submission

Name	View Source	Status
0000944809-22-000026-index-headers.html	Edgar Link	pending
0000944809-22-000026-index.html	Edgar Link	pending
0000944809-22-000026.txt	Edgar Link	pending
0000944809-22-000026-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
opk-20220331.htm	Edgar Link	pending
opk-20220331.xsd	Edgar Link	pending
opk-20220331_cal.xml	Edgar Link	unprocessable
opk-20220331_def.xml	Edgar Link	unprocessable
opk-20220331_htm.xml	Edgar Link	completed
opk-20220331_lab.xml	Edgar Link	unprocessable
opk-20220331_pre.xml	Edgar Link	unprocessable
opk-3312022xex311.htm	Edgar Link	pending
opk-3312022xex312.htm	Edgar Link	pending
opk-3312022xex321.htm	Edgar Link	pending
opk-3312022xex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OPK
OPKO HEALTH, INC. Stock $opk

2022 Q1 Form 10-Q Financial Statement

#000094480922000026 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK OPKO HEALTH, INC. Stock $opk

2022 Q1 Form 10-Q Financial Statement

#000094480922000026 Filed on May 09, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OPK
OPKO HEALTH, INC. Stock $opk